Why the study?
This study evaluated the feasibility and safety of heparin rota-flush solution compared to traditional rota-flush solution in patients undergoing rotational atherectomy.
Does heparin rota-flush solution reduce slow flow/no-reflow in patients undergoing rotational atherectomy compared to traditional rota-flush solution?
Does heparin rota-flush solution reduce slow flow/no-reflow in patients undergoing rotational atherectomy compared to traditional rota-flush solution?
Routine use of heparin rota-flush solution during rotational atherectomy is not supported, as it does not reduce slow flow/no-reflow and increases the risk of coronary spasm compared to traditional rota-flush.
Answers are grounded in this paper and cite their sources.
Does not support routine heparin rota-flush in rotational atherectomy; challenges assumed benefit over traditional solution for slow flow/no-reflow.
INTRODUCTION: This prospective study accessed the feasibility and safety of the heparin rota-flush solution in patients undergoing rotational atherectomy (RA). METHODS: Between August 2019 and November 2021, 200 patients who underwent RA were included in this study, among whom 103 (51.5%) were randomly allocated into the heparin rota-flush group and 97 (48.5%) into the traditional rota-flush group. The primary endpoint was the incidence of slow flow/no-reflow after RA; the secondary endpoints were procedural success, RA-related procedural complications, and in-hospital major adverse cardiovascular events (MACE). RESULTS: There were no significant differences in baseline clinical and angiographic characteristics between the two groups. Thirty patients (29.1%) in the heparin rota-flush group and nineteen patients (19.6%) in the traditional rota-flush groups developed slow flow/no-reflow (P = 0.117), respectively, and procedural success was also comparable (97.1% vs. 93.8%, P = 0.320). Severe hypotension (systolic blood pressure < 90 mmHg) was not significantly different (15.5% vs. 16.5%, P = 0.841), but the incidence of coronary spasm was significantly higher in the heparin rota-flush group (42.7% vs. 22.7%, P = 0.003). MACE including stent-thrombosis (ST), target-lesion revascularization (TLR), and cardiac death were also comparable between the two groups; no stroke was observed. CONCLUSIONS: The findings suggest that although continuous intracoronary infusion of heparin rota-flush solution does not increase the incidence of slow flow/no-reflow, traditional rota-flush solution without RotaGlide prevents coronary spasm more effectively compared to the heparin rota-flush without significant impact on severe hypotension. These results do not support a strategy of routine use of heparin rota-flush solution in patients receiving RA procedures.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: